Williams-Beuren syndrome (WBS) is a microdeletion syndrome caused by haploinsufficiency of genes at 7q11.23. Here we describe the identification and characterization of a novel gene named GTF2IRD1, for GTF2I-repeat domain 1, within the WBS deletion region. Northern blot analysis revealed ubiquitous expression during development with two transcripts of 3.6 kb and 5.0 kb generated by alternative splicing. GTF2IRD1 encodes a protein of 944 amino acids that contains a region of high similarity to a unique motif with helix-loop-helix forming potential occurring within the transcription factor GTF2I. Analogous to TFII-I, the product of GTF2IRD1 may have the ability to interact with other HLH-proteins and function as a transcription factor or as a negative transcriptional regulator. A recent report of the identification of a muscle-specific transcription factor, MusTRD1, supports this hypothesis (O’Mahoney et al., 1998). The open reading frame described for MusTRD1 is identical to that of GTF2IRD1; however, the putative MusTRD1-protein is 486 amino acids shorter than the predicted protein encoded by GTF2IRD1. A heterozygous deletion of GTF2IRD1 may contribute to the complex WBS phenotype.

1.
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J molec Biol 215:403–410 (1990).
2.
Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 25:3389–3402 (1997).
3.
Attwood TK, Beck ME, Flower DR, Scordis P, Selley J: The PRINTS protein fingerprint database in its fifth year. Nucl Acids Res 26:304–308 (1998).
4.
Bairoch A, Bucher P, Hofman K: The PROSITE database, its status in 1997. Nucl Acids Res 25:217–221 (1997).
5.
DeSilva U, Massa H, Trask BJ, Green ED: Comparative mapping of the region of human chromosome 7 deleted in Williams syndrome. Genome Res 9:428–436 (1999).
6.
De Zeeuw CI, Hoogenraad CC, Goedknegt E, Hertzberg E, Neubauer A, Grosveld F, Galjart N: Clip-115, a novel brain-specific cytoplasmic linker protein, mediates the localization of dendritic lamellar bodies. Neuron 19:1187–1199 (1997).
7.
Dilts CV, Morris CA, Leonard CO: Hypothesis for development of a behavioral phenotype in Williams syndrome. Am J med Genet Suppl 6:126–131 (1990).
8.
Dingwall C, Laskey RA: Nuclear targeting sequences—a consensus? Trends Biochem Sci 16:478–481 (1991).
9.
Ferré-D’Amaré AR, Prendergast GC, Ziff EB, Burley SK: Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature 363:38–45 (1993).
10.
Frangiskakis JM, Ewart AK, Morris CA, Mervis CB, Bertrand J, Robinson BF, Klein BP, Ensing GJ, Everett LA, Green ED, Proschel C, Gutowski NJ, Noble M, Atkinson DL, Odelberg SJ, Keating MT: LIM-kinase1 hemizygosity implicated in impaired visuospatial constructive cognition. Cell 86:1–20 (1996).
11.
Grand RJ: Acylation of viral and eukaryotic proteins. Biochem J 258:625–638 (1989).
12.
Grueneberg DA, Henry RW, Brauer A, Novina CD, Cheriyath V, Roy AL, Gilman M: A multifunctional DNA-binding protein that promotes the formation of serum response factor/homeodomain complexes: identity to TFII-I. Genes Develop 11:2482–2493 (1997).
13.
Henikoff S, Henikoff JG: Protein family classification based on searching a data base of blocks. Genomics 19:97–107 (1994).
14.
Hodgkinson CA, Nakayama A, Li H, Swenson L-B, Opdecamp K, Asher JH Jr, Arnheiter H, Glaser T: Mutation at the anophthalmic white locus in Syrian hamsters: haploinsufficiency in the Mitf gene mimics human Waardenburg syndrome type 2. Hum mol Genet 7:703–708 (1998).
15.
Hoogenraad CC, Eussen BHJ, Langeveld A, van Haperen R, Winterberg S, Wouters CH, Grosveld F, De Zeeuw CI, Galjart N: The murine Cyln2 gene: genomic organization, chromosome localization, and comparison to the human gene that is located within the 7q11.23 Williams syndrome critical region. Genomics 53:348–358 (1998).
16.
Horton P, Nakai K: Better prediction of protein cellular localization sites with the k nearest neighbors classifier. Intelligent Systems Mol Biol 5:147–152 (1997).
17.
Howard TD, Paznekas WA, Gree ED, Chiang LC, Ma N, Ortiz de Luna RI, Garcia Delgado C, Gonzalez-Ramos M, Kline AD, Jabs EW: Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nature Genet 15:36–41 (1997).
18.
Kennelly PJ, Krebs EG: Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. J biol Chem 266:15555–15558 (1991).
19.
Kishimoto A, Nishiyama K, Nakanishi H, Uratsuji Y, Nomura H, Takeyama Y, Nishizuka Y: Studies on the phosphorylation of myelin basic protein by protein kinase C and adenosine 3′:5′-monophosphate-dependent protein kinase. J biol Chem 260:12492–12499 (1985).
20.
Kozak M: Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44:283–292 (1986).
21.
Kreil G: Occurrence, detection, and biosynthesis of carboxy-terminal amides. Meth Enzym 106:218–223 (1984).
22.
Li DY, Toland AE, Boak BB, Atkinson DL, Ensing GJ, Morris CA, Keating MT: Elastin point mutations cause an obstructive vascular disease, supravalvular aortic stenosis. Hum mol Genet 6:1021–1028 (1997).
23.
Lu X, Meng X, Morris CA, Keating MT: A novel human gene, WSTF, is deleted in Williams syndrome. Genomics 54:241–249 (1998).
24.
Meng X, Lu X, Morris CA, Keating MT: A novel gene FKBP6 is deleted in Williams syndrome. Genomics 52:130–137 (1998a).
25.
Meng X, Lu X, Li Z, Green ED, Massa H, Trask BJ, Morris CA, Keating MT: Complete physical map of the common deletion region in Williams syndrome and identification and characterization of three novel genes. Hum Genet 103:590–599 (1998b).
26.
Monaco AP: Human genetics: dissecting Williams syndrome. Curr Biol 6:1396–1398 (1996).
27.
Morris CA, Demsey SA, Leonard CO, Dilts C, Blackburn BL: The natural history of Williams syndrome: physical characteristics. J Pediatr 113:318–326 (1988).
28.
Morris CA, Thomas IT, Greenberg F: Williams syndrome: autosomal dominant inheritance. Am J med Genet 47:478–481 (1993).
29.
Murre C, McCaw PS, Baltimore D: A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56:777–783 (1989).
30.
O’Mahoney J, Guven KL, Lin J, Joya JE, Robinson CS, Wade RP, Hardeman EC: Identification of a novel slow-muscle-fiber enhancer binding protein, MusTRD1. Mol Cell Biol 18:6641–6652 (1998).
31.
Osborne LR, Martindale D, Scherer SW, Shi XM, Huizenga J, Heng HHQ, Costa T, Pober B, Lew L, Brinkman J, Rommens J, Koop B, Tsui LC: Identification of genes from a 500-kb region at 7q11.23 that is commonly deleted in Williams syndrome patients. Genomics 36:328–336 (1996).
32.
Osborne LR, Soder S, Shi XM, Pober B, Costa T, Scherer SW, Tsui LC: Hemizygous deletion of the syntaxin 1A gene in individuals with Williams syndrome. Am J hum Genet 61:449–452 (1997).
33.
Osborne LR, Campell T, Daradich A, Scherer SW, Tsui LC: Identification of a putative transcription factor gene (WBSCR11) that is commonly deleted in Williams-Beuren syndrome. Genomics 57:278–284 (1999).
34.
Paperna T, Peoples R, Wang Y-K, Kaplan P, Francke U: Genes for the CPE receptor (CPETR1) and the human homolog of RVP1 (CPETR2) are localized within the Williams-Beuren syndrome deletion. Genomics 54:453–459 (1998).
35.
Peoples R, Pérez-Jurado L, Wang Y-K, Kaplan P, Francke U: The gene for replication factor C subunit 2 (RFC2) is within the 7q11.23 Williams syndrome deletion. Am J hum Genet 58:1370–1373 (1996).
36.
Peoples RJ, Cisco MJ, Kaplan P, Francke U: Identification of the WBSCR9 gene, encoding a novel transcriptional regulator, in the Williams-Beuren syndrome deletion at 7q11.23. Cytogenet Cell Genet 82:238–246 (1998).
37.
Pérez-Jurado LA, Peoples R, Kaplan P, Hamel BCJ, Francke U: Molecular definition of the chromosome 7 deletion in Williams syndrome and parent-of-origin effects on growth. Am J hum Genet 59:781–792 (1996).
38.
Pérez-Jurado LA., Wang Y-K, Peoples R, Coloma A, Cruces J, Francke U: A duplicated gene in the breakpoint regions of the 7q11.23 Williams-Beuren syndrome deletion encodes the initiator binding protein TFII-I and BAP-135, a phosphorylation target of BTK. Hum Mol Genet 7:325–334 (1998).
39.
Pinna LA: Casein kinase 2: an “eminence grise” in cellular regulation? Biochim biophys Acta 1054:267–284 (1990).
40.
Robinson WP, Waslynka J, Bernasconi F, Wang M, Clark S, Kotzot D, Schinzel A: Delineation of 7q11.2 deletions associated with Williams-Beuren syndrome and mapping of a repetitive sequence to within and to either side of the common deletion. Genomics 34:17–23 (1996).
41.
Roy AL, Du H, Gregor PD, Novina CD, Martinez E, Roeder RG: Cloning of an Inr- and E-box-binding protein, TFII-I, that interacts physically and functionally with USF1. EMBO J 16:7091–7104 (1997).
42.
Schuler GD, Boguski MS, Stewart EA, Stein LD, Gyapay G, Rice K, White RE, Rodriguez-Tome P, Aggarwal A, Bajorek E, Bentolila S, Birren BB, Butle A, Castle AB, Chiannilkulchai N, Chu A, Clee C, Cowles S, Day PJ, Dibling T, Drouot N, Dunham I, Duprat S, East C, Hudson TJ, et al: A gene map of the human genome. Science 274:540–546 (1996).
43.
Takeda J, Yano H, Eng S, Yeng Y, Bell GI: A molecular inventory of human pancreatic islets: sequence analysis of 1000 cDNA clones. Hum Mol Genet 2:1793–1798 (1993).
44.
Tassabehji M, Newton VE, Read AP: Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nature Genet 8:251–255 (1994).
45.
Tassabehji M, Metcalfe K, Fergusson WD, Carette MJA, Dore JK, Donnai D, Read AP, Proschel C, Gutowski NJ, Mao X, Sheer D: LIM-kinase deleted in Williams syndrome. Nature Genet 13:272–273 (1996).
46.
Tassabehji M, Metcalfe K, Donnai D, Hurst J, Reardon W, Burch M, Read AP: Elastin: genomic structure and point mutations in patients with supravalvular aortic stenosis. Hum Mol Genet 6:1029–1036 (1997).
47.
Tassabehji M, Metcalfe K, Karmiloff-Smith A, Carette MJ, Grant J, Dennis N, Reardon W, Splitt M, Read AP, Donnai D: Williams syndrome: use of chromosomal microdeletions as a tool to dissect cognitive and physical phenotypes. Am J hum Genet 64:118–125 (1999).
48.
Udwin O: A survey of adults with Williams syndrome and idiopathic infantile hypercalcemia. Dev Med Child Neuro 32:129–141 (1990).
49.
Urban Z, Helms C, Fekete G, Csiszar K, Bonnet D, Munnich A, Donis-Keller H, Boyd CD: 7q11.23 deletions in Williams syndrome arise as a consequence of unequal meiotic crossover. Am J hum Genet 59:958–962 (1996).
50.
Wang PP, Doherty S, Rourke SB, Bellugi U: Unique profile of visuo-perceptual skills in a genetic syndrome. Brain Cognition 29:54–65 (1995).
51.
Wang Y-K, Harryman Samos C, Peoples R, Pérez-Jurado LA, Nusse R, Francke U: A novel human homologue of the Drosophila frizzled wnt receptor gene binds wingless protein and is in the Williams syndrome deletion at 7q11.23. Hum Mol Genet 6:465–472 (1997).
52.
Wang Y-K, Pérez-Jurado LA, Francke U: A mouse single-copy gene, Gtf2i, the homolog of human GTF2I, that is duplicated in the Williams-Beuren syndrome deletion region. Genomics 48:163–170 (1998).
53.
Yang W, Desiderio S: BAP-135, a target for Bruton’s tyrosine kinase in response to B cell receptor engagement. Proc natl Acad Sci, USA 94:604–609 (1997).
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.